{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004097","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.930688+00:00","generated_at":"2026-05-28T05:27:49.637206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Royalty Pharma expects FY 2024 Portfolio Receipts ~$2.8B, at upper end of guidance","bullets":["FY 2024 Portfolio Receipts expected ~$2,800M (upper end of $2,750-$2,800M range).","Underlying Royalty Receipts growth ~13% YoY; Adjusted EBITDA ~$2,560-2,570M.","Capital deployed $2.8B in 2024, record $925M synthetic royalty deals (Rytelo, Niktimvo, Yorvipath).","Late-stage pipeline potential peak royalties >$1.2B/yr; key catalysts: pelacarsen (Phase 3 2025), aficamten (PDUFA Sept 2025).","Announced acquisition of external manager and increased share repurchase commitment (details not provided in this release)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004097","json":"https://secwatch.observer/filing/0001193125-25-004097.json","markdown":"https://secwatch.observer/filing/0001193125-25-004097.md","text":"https://secwatch.observer/filing/0001193125-25-004097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525004097/0001193125-25-004097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525004097/d921741d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:27:49.637206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}